HUTCHMED announces positive results from the FRUSICA-2 trial, showing significant efficacy for the fruquintinib and sintilimab combination in treating advanced renal cell carcinoma. The study demonstrated a median progression-free survival of 22.2 months and an objective response rate of 60.5% compared to standard therapies. Safety data showed a tolerable profile. These results suggest a promising new treatment option for patients with advanced renal cell carcinoma. A New Drug Application for the combination has been accepted for review by the China National Medical Products Administration. Approximately 435,000 new cases of kidney cancer were diagnosed worldwide in 2022, with 90% being renal cell carcinoma. HUTCHMED announced the risks and uncertainties associated with the development of fruquintinib, including enrollment rates, regulatory requirements, and market potential. Investors are advised to review filings with regulatory bodies. The press release also emphasized that the products mentioned may not be available in all countries or under the same trademarks. For more information, investors can contact HUTCHMED directly. Additionally, statistics from the Global Cancer Observatory were referenced, highlighting the need for innovative cancer therapies like fruquintinib in regions such as China with a high incidence of kidney cancer.

Read more at 1. “Apple unveils new iPhone 13 with improved features and camera capabilities.” – CNBC
2. “Tesla announces record-breaking quarter with $1.1 billion in profits.” – Wall Street Journal
3. “FDA approves Pfizer’s COVID-19 vaccine for children ages 5-11.” – Reuters
4. “Amazon reports strong Q3 earnings with $110 billion in revenue.” – Barchart: HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be